Synbiotic HQP08 Supplementation for Hair Loss and Depressive Symptoms: An Open-Label Pilot Study of Clinical Outcomes and Gut Microbiome Changes
Authors:
- Zhilu XuZXZhilu Xu
- Raphaela I. LauRLRaphaela I. Lau
- Haoyu QiHQHaoyu Qi
- Martin C. S. WongMartin C. S. Wong
- Kingsley H. N. ChanKCKingsley H. N. Chan
- Ivan S. F. LauILIvan S. F. Lau
- Jessica Y. L. ChingJCJessica Y. L. Ching
- Pui Kuan CheongPCPui Kuan Cheong
- Francis K. L. ChanFrancis K. L. Chan
- Siew C. NgSNSiew C. Ng
Open Access
Abstract
Background: Gut microbiota dysregulation has been implicated in hair loss via the gut–skin axis, but human interventional data are limited. We previously showed that Bifidobacterium longum HK003 reverses alopecia-like phenotypes in mice. Methods: We conducted an open-label, single-arm pilot study to evaluate an HK003-containing synbiotic (HQP08) in 32 adults with self-reported hair loss over 8 weeks. The primary endpoint was the proportion of participants reporting improvement on the Patient Global Impression of Change (PGI-C) scale at week 8. Secondary outcomes included changes in hair loss severity, 60 s hair count, depressive symptoms (PHQ-9), safety, and gut microbiome composition (Chinese Clinical Trial Registry ChiCTR2500112698). Results: At week 8, 62.5% (20/32) of participants reported PGI-C improvement. Significant reductions were observed in hair loss severity (p = 0.0008), 60 s hair count (p = 0.0048), and PHQ-9 scores (p = 0.002). Younger age was associated with PGI-C response (OR per year 0.86, 95% CI: 0.73–0.98, p = 0.037). Metagenomic analysis identified engraftment of B. longum HK003-like profiles in a subset of participants at week 12. Changes in microbial pathways related to thiamine metabolism, vitamin B12 salvage, and lipopolysaccharide biosynthesis were associated with ΔPHQ-9 (FDR-adjusted p < 0.05), but not with hair-related endpoints. No serious adverse events occurred. Conclusions: This first-in-human pilot study suggests that HQP08 was well tolerated and was associated with within-participant changes in hair-loss measurements and PHQ-9 scores. Randomized controlled trials are warranted to confirm efficacy and further elucidate mechanisms within the gut–brain–skin axis.Keywords
Funding Information
- InnoHK Initiative of the Innovation and Technology Commission of the Hong Kong Special Administrative Region Government
This publication has 39 references indexed in Scilit:
- Cutaneous and Gut Dysbiosis in Alopecia Areata: A ReviewJID Innovations, 2025
- Bifidobacterium longum CECT 30763 improves depressive- and anxiety-like behavior in a social defeat mouse model through the immune and dopaminergic systemsBrain, Behavior, and Immunity, 2024
- Vitamin-mediated interaction between the gut microbiome and mitochondria in depression: A systematic review-based integrated perspectiveBrain, Behavior, & Immunity - Health, 2024
- Characterization of distinct microbiota associated with androgenetic alopecia patients treated and untreated with platelet‐rich plasma (PRP)Animal Models and Experimental Medicine, 2024
- A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trialThe Lancet Infectious Diseases, 2023
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trialThe Lancet, 2023
- Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male PatientsJAMA Dermatology, 2022
- Adaptive Evolution within Gut Microbiomes of Healthy PeopleCell Host & Microbe, 2019
- Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome FeaturesCell, 2018
- Stable Engraftment of Bifidobacterium longum AH1206 in the Human Gut Depends on Individualized Features of the Resident MicrobiomeCell Host & Microbe, 2016